Medplus Health Services has reported a temporary setback for its subsidiary, Optival Health Solutions Private Limited, in Karnataka. The company disclosed this information in a regulatory filing to the stock exchanges on August 2, 2025.

Suspension Details

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received a suspension order for its drug license at a store located in Rampure colony bider exp, Karnataka. The Assistant Director of Drugs Control Administration, Bangalore Circle – Bidar issued the two-day suspension under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Timeline and Financial Impact

The suspension order was received on August 1, 2025. Medplus estimates a potential revenue loss of approximately Rs. 0.18 lakhs for the affected store during the suspension period.

Regulatory Compliance

The company has promptly disclosed this information in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure also aligns with recent SEBI circulars dated July 13, 2023, and December 31, 2024, which mandate prompt reporting of such incidents.

Company Response

Medplus Health Services has stated that the details of this suspension will be available on the company's website ( www.medplusindia.com ) as well as on the websites of BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Ltd. ( www.nseindia.com ).

While the immediate financial impact appears limited, this incident highlights the regulatory challenges faced by pharmaceutical retail chains in India.

Medplus Health Services Limited , a prominent player in the Indian pharmacy retail sector, has reported that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Telangana. This development comes as a result of regulatory action taken by the Assistant Director of Drugs Control Administration in Warangal, Telangana.

Suspension Details

The company disclosed that the suspensions affect two stores:

1. A store situated at Station Ghanpur, facing a five-day suspension
2. A store located on Girinigadda main road, Jangaon, Warangal, subject to a three-day suspension

These actions were taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945, indicating violations of pharmaceutical regulations.

Financial Impact

MedPlus Health Services has provided estimates of the potential financial impact resulting from these suspensions:

While these figures represent a relatively minor financial setback for the company, they underscore the importance of regulatory compliance in the pharmaceutical retail sector.

Regulatory Disclosure

In compliance with SEBI regulations, MedPlus Health Services Limited has formally notified both the BSE Limited and the National Stock Exchange of India Limited about this development. The company has assured that detailed information regarding this matter will be made available on its official website, as well as on the websites of the respective stock exchanges.

Implications for MedPlus

These suspensions, while limited in duration and scope, highlight the stringent regulatory environment in which pharmaceutical retailers operate. For MedPlus, a company with a widespread presence in the Indian market, maintaining compliance across its network of stores remains a critical operational focus.

The incident serves as a reminder of the ongoing challenges faced by pharmacy chains in adhering to the complex web of regulations governing the sale and distribution of medicines in India. It also underscores the importance of robust internal controls and compliance mechanisms to prevent such occurrences in the future.

As the company works to address these regulatory issues, investors and stakeholders will likely be watching closely to see how MedPlus manages its compliance processes and mitigates the risk of similar incidents across its broader network of stores.